| 6T3J: reference: Dual epitope targeting and enhanced hexamerization by DR5 antibodies as a novel approach to induce potent anti-tumor activity through DR5 agonism., Overdijk MB, Strumane K, Beurskens FJ, Ortiz Buijsse A, Vermot-Desroches C, Vuillermoz BS, Kroes T, Jong B, Hoevenaars N, Hibbert RG, Lingnau A, Forssmann U, Schuurman J, Parren PWHI, de Jong RN, Breij ECW, Mol Cancer Ther. 2020 Aug 26. pii: 1535-7163.MCT-20-0044. doi:, 10.1158/1535-7163.MCT-20-0044. PMID: 32847982 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).